$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
使用厄达替尼,生活中应该注意什么?
2025-10-19 11:44:20
Check Details
厄达替尼的疗效怎么样呢?厄达替尼的副作用有哪些?
2025-10-19 11:44:20
Check Details
FDA批准厄达替尼(Erdafitinib)靶向治疗转移性膀胱癌
2025-10-19 11:44:20
Check Details
首款治疗膀胱癌的靶向药厄达替尼获批上市!
2025-10-19 11:44:20
Check Details
EG-70对卡介苗无反应的非肌层浸润性膀胱癌显示出良好的临床疗效
2025-10-19 11:44:20
Check Details
Padcev或将成为不适用于顺铂化疗的肌肉浸润性膀胱癌患者的治疗新选择
2025-10-19 11:44:20
Check Details
膀胱癌首款靶向药厄达替尼获批上市!
2025-10-19 11:44:20
Check Details
厄达替尼的使用方法和副作用你知道吗?
2025-10-19 11:44:20
Check Details
膀胱癌首款靶向药厄达替尼Erdafitinib疗效如何
2025-10-19 11:44:20
Check Details
厄达替尼现在能够在滨州购买到吗?
2025-10-19 11:44:20
Check Details
厄达替尼有忌口吗,生活中要注意什么?
2025-10-19 11:44:20
Check Details
厄达替尼的不良反应是什么,如何处理?
2025-10-19 11:44:20
Check Details
1
2
...
6289
6290
6291
6292
6293
6294
6295
...
10232
10233
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
2
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance
3
Lorlatinib Contraindications and Safety Warnings: Six Key Risks to Monitor
4
AZA+VEN+IVO Triplet Therapy for Newly Diagnosed IDH1 AML: High Response Rates and Durable Efficacy
5
Dacomitinib for EGFR-Mutant NSCLC: Dosing, Switching, and Safety Profile
6
Abemaciclib for HR+ HER2- Breast Cancer: Mechanism, Combination Therapy, and Switching Considerations
7
Fezolinetant (Veozah) Dosing and Liver Monitoring Guide
8
Lusutrombopag Safety and Dosing: Thrombosis Risk and Indications
9
Mirogabalin for Neuropathic Pain: Onset Time and Dosing Strategy
10
Cemiplimab Mechanism of Action: How PD-1 Inhibition Restores Antitumor Immunity
11
Tivozanib Dosing Guide for Renal Cell Carcinoma: 21-Day On/7-Day Off Cycle and Adjustments
12
Anagrelide and Myelofibrosis Risk: Controversy and Monitoring in ET Treatment